中国实用内科杂志2018，Vol.38Issue(5)：446-450,5.DOI:10.19538/j.nk2018050109
慢性阻塞性肺疾病急性加重糖皮质激素应用现状与依据
Current situation and evidence of glucocorticoid therapy for acute exacerbation of chronic obstructive pulmonary disease
摘要
Abstract
Exacerbations of chronic obstructive pulmonary disease (COPD) are important events in the management of COPD because they negatively impact health status, rates of hospitalization and readmission, and disease progression. However, currently, inappropriate and irrational use of glucocorticoids is quite common in the process of the treatment of acute exacerbation of COPD. For example, there are problems in the drug population, type, dosage form, dosage, drug delivery pathway, course of treatment, withdrawal, etc., which lead to a series of side effects. Proper use of glucocorticoids can improve lung function (FEV1), oxygenation and shorten recovery time. This article reviews the current use of glucocorticoid in treatment of AECOPD, outlines the recent global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease and the expert consensus of acute exacerbation, and explores the role of glucocorticoid in the treatment of AECOPD ibased on evidence-based medicine.关键词
慢性阻塞性肺疾病/急性加重/糖皮质激素/治疗现状Key words
chronic obstructive pulmonary disease/acute exacerbation/glucocorticoid/treatment status分类
医药卫生引用本文复制引用
孙婉璐,陈亚红..慢性阻塞性肺疾病急性加重糖皮质激素应用现状与依据[J].中国实用内科杂志,2018,38(5):446-450,5.基金项目
国家重点研发计划(2016YFC1304301) （2016YFC1304301）
